← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE › Progestogens and estrogens, fixed combinations
lynestrenol and ethinylestradiol
G03AA03
Forms & Strengths
- Tablet: lynestrenol 1 mg / ethinylestradiol 0.05 mg
- Tablet: lynestrenol 2.5 mg / ethinylestradiol 0.05 mg
- Tablet: lynestrenol 2.75 mg / ethinylestradiol 0.01 mg
Adult Dosing
- Contraception: 1 tablet daily for 21 consecutive days, followed by a 7-day pill-free interval
- Menstrual disorders: 1 tablet daily for 21 days per cycle as directed for specific endocrine indication
Pediatric Dosing
- Post-menarchal adolescents: 1 tablet daily following the same adult schedule for contraception or cycle regulation
Indications
- Oral contraception
- Treatment of menstrual disorders such as menorrhagia, dysmenorrhea, and secondary amenorrhea
Mechanism of Action
- Suppression of gonadotropins (FSH and LH) by estrogen and progestin components
- Inhibition of ovulation
- Alteration of cervical mucus to impede sperm penetration
- Modification of the endometrium to prevent blastocyst implantation
Contraindications
- Known or suspected pregnancy
- Active venous thromboembolism (VTE) or arterial thromboembolism
- History of or current cerebrovascular disease or coronary artery disease
- Known or suspected sex hormone-dependent malignancies
- Severe hepatic impairment or liver tumors
- Undiagnosed abnormal uterine bleeding
- Hypersensitivity to lynestrenol, ethinylestradiol, or any excipient
Adverse Reactions
- Venous and arterial thromboembolism
- Hypertension
- Nausea, abdominal cramping, bloating
- Headache, migraine
- Breast tenderness, enlargement
- Weight fluctuations
- Mood changes, depression
- Breakthrough bleeding, amenorrhea
Drug Interactions
- CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) decrease contraceptive efficacy
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase plasma concentrations
- Antidiabetic agents: hormonal contraceptives may impair glucose tolerance, requiring dosage adjustments
- Lamotrigine: estrogen-containing contraceptives decrease lamotrigine plasma concentrations, increasing seizure risk
- Bile acid sequestrants reduce absorption of ethinylestradiol
Curated Content: Needs Vetting Before Put to Clinical Use